Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders
Pharmacological Reports · 2024-12 · 76 (6) · 1333-1345
DOI: 10.1007/s43440-024-00654-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reports, online erschienen am 03.10.2024. Verfasst von Tansu Göver und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lukasiewicz Research Network - PORT Polish Center for Technology Development, ul. Stabłowicka 147, 54-066, Wroclaw, Poland. Hauptthemen laut MEDLINE: Receptors, Glucocorticoid, Signal Transduction. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education, Poland, National Science Center, Poland.
Abstract (Originalsprache)
The hypothalamic–pituitary–adrenal (HPA) axis plays a central role in governing stress-related disorders such as major depressive disorder (MDD), anxiety, and post-traumatic stress disorder. Chronic stress or early life trauma, known risk factors of disease, alter HPA axis activity and pattern of glucocorticoid (GC) secretion. These changes have consequences for physiological processes controlled by glucocorticoid receptor (GR) signaling, such as immune response and metabolism. In the brain, the aberrant GR signaling translates to altered behavior, making the GR pathway a viable target for therapies of stress-related disorders. One of the crucial elements of the pathway is FKBP5, a regulator of GR sensitivity and feedback control within the HPA axis, in which genetic variants were shown to moderate the risk of developing psychiatric conditions. The difficulty in targeting the GR-FKBP5 pathway stems from tailoring the intervention to specific brain regions and cell types, in the context of personalized genetic variations in GR and GR-associated genes, like FKBP 5. The development of selective inhibitors, antagonists, and approaches based on targeted protein degradation offer insights into mechanistic aspects of disease and pave the way for improved therapy. These strategies can be employed either independently or in conjunction with conventional medications. Concomitant advancements in personalized drug screening (e.g. in vitro models exploiting induced pluripotent stem cells, iPSCs) bring the potential for optimization of therapy aiming to rescue central deficits originating from the HPA imbalance. In this mini-review, we discuss potential therapeutic strategies targeting GR signaling in stress-related disorders, with a focus on personalized approaches and advancements in drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lukasiewicz Research Network - PORT Polish Center for Technology Development, ul. Stabłowicka 147, 54-066, Wroclaw, Poland.
- Department of Biophysics and Neuroscience, Wroclaw Medical University, ul. Chałubińskiego 3A, 50-368, Wroclaw, Poland.
- Lukasiewicz Research Network - PORT Polish Center for Technology Development, ul. Stabłowicka 147, 54-066, Wroclaw, Poland. Michal.Slezak@port.lukasiewicz.gov.pl.
Förderung
- Ministry of Science and Higher Education, Poland
- National Science Center, Poland
Zitieren
APA
Göver, T., & Slezak, M. (2024). Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders. Pharmacological Reports, 76(6), 1333-1345. https://doi.org/10.1007/s43440-024-00654-w
Vancouver
Göver T, Slezak M. Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders. Pharmacological Reports. 2024;76(6):1333-1345. doi:10.1007/s43440-024-00654-w
BibTeX
@article{Gver2024,
author = {Göver, Tansu and Slezak, Michal},
title = {Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders},
journal = {Pharmacological Reports},
year = {2024},
volume = {76},
number = {6},
pages = {1333--1345},
doi = {10.1007/s43440-024-00654-w}
}
EUVIMED